News
AMRX
18.14
+0.39%
0.07
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 2d ago
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality
Simply Wall St · 3d ago
Amneal Pharmaceuticals price target raised to $25 from $23 at UBS
TipRanks · 6d ago
Amneal (AMRX) Q2 2026 Earnings Call Transcript
The Motley Fool · 6d ago
Amneal Pharmaceuticals Reprices Term Loans to Reduce Interest
TipRanks · 6d ago
Amneal Pharmaceuticals Is Maintained at Buy by UBS
Dow Jones · 6d ago
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25
Benzinga · 6d ago
Did Strong Q2 Results and Higher 2026 Revenue Guidance Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?
Simply Wall St · 08/03 10:17
Weekly Report: what happened at AMRX last week (0727-0731)?
Weekly Report · 08/03 10:08
Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance
Simply Wall St · 08/02 06:13
Amneal Pharmaceuticals’ Earnings Call Signals Strong Growth
TipRanks · 08/02 00:04
Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure
Simply Wall St · 07/31 22:52
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Seeking Alpha · 07/31 21:15
Amneal Stockholders Approve Kashiv BioSciences Acquisition Plans
TipRanks · 07/31 20:31
Amneal Pharmaceuticals price target raised to $21 from $19 at Goldman Sachs
TipRanks · 07/31 11:10
Amneal (AMRX) Q2 2026 Earnings Call Transcript
The Motley Fool · 07/31 02:17
At a glance: stocks gapping up premarket
Seeking Alpha · 07/30 11:11
Amneal Raises 2026 Outlook After Strong Q2 Results
TipRanks · 07/30 10:45
More
Webull provides a variety of real-time AMRX stock news. You can receive the latest news about Amneal Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.